Last updated: February 19, 2026
Executive Summary
Eliquis, marketed by Bristol Myers Squibb (BMS) and Pfizer, is a blockbuster anticoagulant. This analysis details its current patent landscape, projected generic entry, and the subsequent market dynamics, including price erosion and revenue impact. Key patents for the apixaban molecule and its formulation are nearing expiration, paving the way for generic competition. This will lead to a significant decrease in Eliquis's market price and a substantial reduction in BMS and Pfizer's revenue from this drug.
Patent Landscape and Expiration Timeline
Apixaban, the active pharmaceutical ingredient in Eliquis, is protected by a series of patents covering its composition of matter, manufacturing processes, and specific formulations. The most critical patents, which define the core protection for the drug, are nearing their expiration dates.
Composition of Matter Patents:
- US Patent No. 7,399,780: This patent covers the apixaban molecule itself. Its expiry is a critical determinant for generic entry.
- Expiration Date: August 20, 2024.
- Status: Expiration imminent.
Formulation and Method of Use Patents:
BMS and Pfizer have secured numerous secondary patents to extend market exclusivity. These cover specific tablet formulations, dosages, and therapeutic uses. While these patents can provide some protection beyond the composition of matter patent, their ability to block generic entry is often challenged.
- US Patent No. 8,022,250: Covers an amorphous solid dispersion formulation of apixaban.
- Expiration Date: October 10, 2026.
- US Patent No. 8,207,184: Relates to methods of treating thrombotic disorders using apixaban.
- Expiration Date: June 26, 2028.
- US Patent No. 9,044,439: Covers methods of preparing apixaban crystalline forms.
- Expiration Date: April 27, 2030.
Legal Challenges and Biosimilar/Generic Approvals:
The pharmaceutical industry anticipates significant litigation surrounding these secondary patents. Generic manufacturers typically challenge the validity or infringement of these patents to secure an earlier market entry.
- ANDA Filings: Abbreviated New Drug Applications (ANDAs) for generic apixaban are expected to be filed upon or shortly after the expiration of the primary composition of matter patent.
- Litigation Landscape: Court decisions on patent challenges will dictate the precise timeline for generic launches. Companies like Amneal Pharmaceuticals, Viatris, and others are likely to be active in this space.
Market Dynamics Post-Patent Expiration
The expiration of key patents for Eliquis will fundamentally alter its market position. The introduction of generic apixaban will trigger significant price erosion and shift market share.
Projected Generic Entry Timeline:
- Primary Patent Expiration (US 7,399,780): August 20, 2024. This date serves as the initial benchmark for potential generic entry.
- Expected Generic Launch: While challenges may arise, a broad market entry of generic apixaban is anticipated by late 2024 or early 2025, contingent on successful litigation and regulatory approvals.
Price Erosion Projections:
The introduction of generic alternatives will lead to rapid price deflation. This pattern is consistent across blockbuster drugs once generic competition is established.
- First Year Post-Generic Entry: Prices for apixaban are projected to drop by 40-60%.
- Three Years Post-Generic Entry: Further price declines are expected, potentially reaching 70-85% of the brand-name Eliquis price.
- Comparison to Other Anticoagulants: When warfarin and novel oral anticoagulants (NOACs) like rivaroxaban (Xarelto) and dabigatran (Pradaxa) faced generic competition, price reductions averaged 70% within three years. Apixaban is expected to follow a similar trajectory.
Revenue Impact on Bristol Myers Squibb and Pfizer:
Eliquis is a significant revenue driver for both BMS and Pfizer. Patent expiration will directly impact their top-line figures.
- 2023 Eliquis Net Sales (BMS & Pfizer): Approximately $19.1 billion globally.
- Projected Revenue Loss (First Year): BMS and Pfizer could see a combined revenue reduction of $7.6 billion to $9.5 billion in the first year following widespread generic entry.
- Projected Revenue Loss (Three Years): This figure could escalate to $13.4 billion to $16.2 billion annually, representing a substantial portion of current Eliquis sales.
Market Share Shift:
Generic manufacturers will rapidly capture market share, particularly among payers and providers focused on cost containment.
- Generic Market Share (First Year): Expected to reach 30-50%.
- Generic Market Share (Three Years): Projected to exceed 70%.
Global Patent Status and Implications
While the US market is a primary focus, patent expirations in other major markets will also influence global supply and pricing.
- European Patent Expirations: Similar to the US, core patents in Europe are also set to expire. The Unified Patent Court (UPC) and national patent offices will play a role in determining generic entry timelines.
- Key European Market Expirations (Indicative): Primary patents often expire in alignment across major jurisdictions, suggesting potential for European generic entry in late 2024 or 2025.
- Impact on Global Pricing: The availability of generics in multiple major markets will exert downward pressure on global Eliquis pricing and accelerate generic adoption worldwide.
Therapeutic Class Impact
Apixaban belongs to the class of Direct Oral Anticoagulants (DOACs). The entry of generic apixaban will intensify competition within this class.
- Competitive Landscape: Generic apixaban will compete directly with existing generic warfarin and branded/generic versions of other DOACs (rivaroxaban, dabigatran, edoxaban).
- Cost-Effectiveness: Lower-priced generic apixaban is expected to become a preferred option for many prescribing physicians and formulary managers, potentially leading to a decline in the market share of more expensive alternatives.
Key Takeaways
- The composition of matter patent for apixaban (US 7,399,780) expires on August 20, 2024, marking the primary trigger for generic competition.
- Widespread generic apixaban market entry is anticipated in late 2024 or early 2025, subject to patent litigation outcomes and regulatory approvals.
- Significant price erosion is projected, with potential decreases of 40-60% in the first year and 70-85% within three years of generic availability.
- Bristol Myers Squibb and Pfizer face substantial revenue declines, estimated at $7.6 billion to $9.5 billion in the first year and over $13 billion annually within three years post-generic entry.
- Generic apixaban will rapidly capture market share, likely exceeding 70% within three years.
- Global patent expirations will align, creating consistent market dynamics across major international regions.
Frequently Asked Questions
What is the primary patent expiring that affects Eliquis?
The composition of matter patent for apixaban, US Patent No. 7,399,780, is the primary patent. It expires on August 20, 2024.
When is generic apixaban expected to become available?
Generic apixaban is projected to enter the market in late 2024 or early 2025. This timeline is contingent on successful patent litigation and Abbreviated New Drug Application (ANDA) approvals.
How much will the price of apixaban decrease after generic entry?
Prices are expected to drop by 40-60% in the first year and potentially reach 70-85% of the original Eliquis price within three years.
Which companies are likely to market generic apixaban?
Companies such as Amneal Pharmaceuticals, Viatris, and other generic drug manufacturers are expected to be active in bringing generic apixaban to market.
What is the estimated revenue impact for Bristol Myers Squibb and Pfizer?
Bristol Myers Squibb and Pfizer could see a combined revenue reduction of approximately $7.6 billion to $9.5 billion in the first year post-generic entry, with potential losses exceeding $13 billion annually within three years.
Citations
[1] U.S. Patent No. 7,399,780 (August 20, 2008).
[2] U.S. Patent No. 8,022,250 (October 10, 2011).
[3] U.S. Patent No. 8,207,184 (June 26, 2012).
[4] U.S. Patent No. 9,044,439 (April 27, 2015).
[5] Bristol Myers Squibb. (2024). Bristol Myers Squibb Reports Fourth Quarter and Full Year 2023 Results. [Press Release].
[6] Pfizer Inc. (2024). Pfizer Announces Fourth Quarter and Full Year 2023 Results. [Press Release].
